OncoC4 is a privately-held, late-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.

GSK’s vaccines business is one of the largest in the world. It has the broadest portfolio of the industry, making available 39 pediatric, adolescent, adult and traveler vaccines that protect against 21 different diseases including hepatitis, meningitis, influenza, pneumococcal disease and rotavirus. GSK has 15 candidate vaccines in development against diseases including shingles, RSV, Group B Strep and COPD exacerbations. Over 1.9 million vaccines are delivered by GSK everyday to people across more than 150 countries worldwide.GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com/about us.

We develop your assays and manage global logistics, speeding to actionable answers. We use biomarkers to stratify patients, incomparably improving your R&D efficiency and success. We manage every aspect of your clinical trials from sites to biomarkers to diagnostics, all under a single roof. In short: we dramatically accelerate your pathway from proof of concept to drug approval.

Champions Oncology’s TumorGraft platform and Translational Oncology Solutions is an innovative platform technology able to accelerate the development of oncology drugs by predicting their clinical effectiveness.This platform is based on primary tumor models of cancer that preserve the original characteristics of the human tumor. As a result, Champions TumorGraft® (CTG) technology is more predictive than traditional xenograft models and has a nearly 1:1 correlation rate to actual patient outcomes.

The Molecular Radiation Therapeutics Branch (MRTB) was initiated in June of 2001 with the goal of developing target based strategies for enhancing tumor sensitivity and protecting normal tissue during radiotherapy.